Exosome Diagnostics, Inc.
Biomarker Discovery Services
Exosome Diagnostics partners with biopharma companies and Clinical Centers of Excellence to facilitate biomarker discovery programs in support of early discovery, translational, and clinical programs that may have companion diagnostic development needs.
Most popular related searches
biomarker discovery
biomarker
diagnostics development
clinical program
tissue specific
mrna
biopharmaceutical
tissue cell
tissue cells
Proprietary Platforms used for Biomarker Discovery
Our biomarker discovery capabilities are broad and provide the ability to analyze and quantitatively measure RNAs, cfDNA, and specific cell or tissue types using our proprietary platforms:
- Exolution RNA: analyze and quantitatively measure small and long RNAs, including non-coding RNA, mRNA, miRNAs, isoforms, and FUSIONS.
- Exolution Plus: measure cfDNA in addition to exoRNA to further enhance mutation detection.
- Exosome Diagnostics Depletion or Enrichment (EDDE): our unique platform uses tissue-specific biomarkers to selectively enhance exosome selection. This distinctive capability, combined with our other proprietary exosome isolation platforms, can generate cell-specific assays. See Exosome Enrichment Capabilities.